You are leaving this site. You are about to leave www.grantforfertilityinnovation.com. The content of the site you are about to visit is not controlled by grantforfertilityinnovation.com.
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is a leading U.S. biopharma company focused exclusively on specialty care.
For more than 40 years, EMD Serono has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono has more than 1,100 employees around the country with commercial, clinical and research operations based in the company’s home state of Massachusetts.
For more information, please visit www.emdserono.com.
EMD Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biologic origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of oncology, neurology and immunology.
To learn more about other Grants for Innovation in other therapeutic areas, please visit: www2.grantforgrowthinnovation.org/EMDSerono/index.html; www2.grantformultiplesclerosisinnovation.org/EMDSerono/index.html;